Navigation Links
Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
Date:8/2/2012

REDWOOD CITY, Calif., Aug. 2, 2012 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal fourth quarter and year ended June 30, 2012. Cardica's management will hold a conference call at 4:30 p.m. Eastern Daylight Time to discuss the financial results and provide an update on the company's business.

"We continue to gain experience and feedback for our MicroCutter XCHANGE™ 30, as more than 30 surgeons at six hospitals across Germany have used the device to successfully complete a wide variety of surgical procedures," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "Having incorporated feedback and suggestions from surgeons into the design and functionality of this product, which is substantially smaller than conventional stapling devices, we have resumed the European clinical study and plan to begin booking commercial sales in the second half of calendar 2012."

Recent Highlights and Accomplishments

  • Completed over 250 deployments in more than 80 procedures with the XCHANGE 30 device prior to resuming the clinical trial in Europe including procedures such as appendectomies, vascular transections, intestinal and lung resections;
  • Resumed the European clinical trial for the MicroCutter cutting/stapling device and to date have enrolled 10 patients at four centers throughout Germany;
  • Increased cumulative worldwide shipments of PAS-Port® Proximal Anastomosis Systems to over 28,500 units, with 1,212 units shipped in the fiscal 2012 fourth quarter; and,
  • Increased cumulative worldwide shipments of C-Port® Distal Anastomosis Systems to over 13,100, with 182 units shipped in the fiscal 2012 fourth quarter.
  • Fiscal 2012 Fourth Quarter and Year Ended June 30, 2012 Financial Results
    Total product sales were approximate
    '/>"/>

    SOURCE Cardica, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
    2. Cardica Announces Fiscal 2012 Third Quarter Financial Results
    3. Law Office of Brodsky & Smith, LLC Announces Settlements of Yaz, and Yasmin Cases
    4. BD Announces Results For 2012 Third Fiscal Quarter
    5. Alexza Announces Management Promotions
    6. Solta Medical, Inc. Announces Proposed Public Offering of Common Stock
    7. The American Society of Interventional Pain Physicians Announces Guidelines for Responsible Prescribing of Pain-Killers for Chronic Non-Cancer Pain
    8. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    9. Omnicell Announces Second Quarter 2012 Results
    10. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
    11. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
    (Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
    (Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
    Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
    ... Novavax, Inc.,(Nasdaq: NVAX ) announced today ... trial of its non-adjuvanted pandemic influenza virus-like,particle (VLP) ... Officer and Head of Clinical,Development stated, "The initial ... support further development of our pandemic influenza vaccine,through ...
    ... announce the,recent publication of important results from research into ... compounds, C75. The,Company is a leader in the research ... area of that research has been for the treatment,of ... is centered in the hypothalamus in the brain, research ...
    Cached Medicine Technology:Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4FASgen Announces New Discovery for Treatment of Stroke 2
    (Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
    (Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
    (Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
    (Date:9/19/2014)... -- More states are passing legislation permitting or requiring ... any child having a severe allergic reaction. Epinephrine ... reaction that can lead to throat swelling, breathing difficulties, ... In people with severe allergies to certain ... or certain drugs, anaphylaxis can occur within moments of ...
    (Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
    Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
    ... Inc's brand cleansing solution has been linked to a severe ... Optometry doctors in the U.S have urged contact lens wearers ... Bausch & Lomb Inc. has stopped shipping ... following warnings from the U.S. Food and Drug Administration (FDA) ...
    ... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
    ... from far but far from good! A city that has ... life// , might not be promoting feelings of well-being in ... happen to be a highly distressed lot compared to the ... cause of distress, opining that nearly one out of seven ...
    ... Ontario plans to revamp the drug system. Health Minister ... to improve the drug program//. He also said that ... drug system transparent and sustainable. They will also speed ... voices are heard. The taxpayers have not received fair ...
    ... in the April issue of IJCP, the International Journal ... of cases of invasive// pneumococcal diseases (IPD) like meningitis ... still only vaccinate selected at-risk groups against IPD. ... vaccination of infants and young children reduces their risk ...
    ... obesity is due at least in part to an ... when to stop eating, and a protein more recently// ... protein (CRP) not only binds to leptin but its ... The results may help explain why obese people have ...
    Cached Medicine News:Health News:Promotion of Pneumococcal Vaccine Slow in Europe 2Health News:Promotion of Pneumococcal Vaccine Slow in Europe 3Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3
    ... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
    ... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
    ... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
    ... Clopidogrel Assay measures changes in platelet ... Clopidogrel (Plavix). It uses a specific ... clopidogrel inhibits. The assay has not ... the assay is available for Research ...
    Medicine Products: